Flag of the European Union EU Clinical Trials Register Help

Clinical trials for eudract

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44349   clinical trials with a EudraCT protocol, of which   7376   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    227 result(s) found for: eudract. Displaying page 11 of 12.
    «« First « Previous 4  5  6  7  8  9  10  11  12  Next»
    EudraCT Number: 2005-003944-68 Sponsor Protocol Number: EGF105084 Start Date*: 2006-02-15
    Sponsor Name:GlaxoSmithKline R&D Ltd
    Full Title: A Phase II Study of Lapatinib for Brain Metastases in Subjects with ErbB2-Positive Breast Cancer Following Trastuzumab based Systemic Therapy and Cranial Radiotherapy
    Medical condition: Progressive symptomatic or asymptomatic ErbB2 overexpressing breast cancer brain metastases.
    Disease: Version SOC Term Classification Code Term Level
    8.1 10027475 Metastatic breast cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) AT (Completed) DE (Completed) GB (Completed) BE (Completed) ES (Completed) GR (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2012-005588-28 Sponsor Protocol Number: 000080 Start Date*: 2013-06-04
    Sponsor Name:Ferring International Pharmascience Center US, Inc.
    Full Title: A Double-blind, Randomised, Placebo-controlled, Phase 3 Trial in Patients with Chronic Idiopathic Constipation to Demonstrate the Efficacy and Safety of Elobixibat 5 mg and 10 mg for 12 Weeks Follo...
    Medical condition: Chronic idiopathic constipation
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004856 10072118 Chronic idiopathic constipation LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Prematurely Ended) DE (Completed) SK (Completed) HU (Prematurely Ended) CZ (Prematurely Ended) GB (Prematurely Ended) PL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2021-004931-10 Sponsor Protocol Number: R3918-PNH-2050 Start Date*: 2022-12-27
    Sponsor Name:REGENERON PHARMACEUTICALS, INC.
    Full Title: An Open-Label Extension Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of Pozelimab and Cemdisiran Combination Therapy in Patients with Paroxysmal Nocturnal Hemoglobinuria
    Medical condition: Paroxysmal nocturnal hemoglobinuria (PNH)
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004857 10055629 Paroxysmal nocturnal hemoglobinuria LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Trial now transitioned) PL (Trial now transitioned) GR (Trial now transitioned) HU (Trial now transitioned) ES (Ongoing) RO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2017-001465-24 Sponsor Protocol Number: GC-LTFU-001 Start Date*: 2018-02-26
    Sponsor Name:Celgene Corporation
    Full Title: Long-Term Follow-up Protocol for Subjects Treated with Gene-Modified T cells.
    Medical condition: Defined by parent protocol. The study will enroll all adult and paediatric subjects who received at least one genetically modified T cells infusion in a previous Celgene sponsored study.
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10025631 Malignant lymphoid neoplasm NOS LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Trial now transitioned) DE (Trial now transitioned) ES (Ongoing) NL (Trial now transitioned) AT (Trial now transitioned) FR (Trial now transitioned) FI (Trial now transitioned) SE (Trial now transitioned) GB (GB - no longer in EU/EEA) NO (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2013-004495-34 Sponsor Protocol Number: iMAP2 Start Date*: 2014-03-11
    Sponsor Name:Public Health England
    Full Title: A randomised controlled trial comparing two pertussis-containing vaccines in pregnancy and vaccine responses in UK mothers and their infants (immunising Mums Against Pertussis, iMAP2)
    Medical condition: No medical condition or disease, instead responses to immunisations against pertussis (whooping cough) in mothers and against pertussis (whooping cough), tetanus, diphtheria, Hib, meningococcal C a...
    Disease: Version SOC Term Classification Code Term Level
    16.1 10018065 - General disorders and administration site conditions 10059080 Vaccination site reaction PT
    16.1 10042613 - Surgical and medical procedures 10054175 Polio immunisation PT
    16.1 10042613 - Surgical and medical procedures 10054131 Tetanus immunisation PT
    16.1 10042613 - Surgical and medical procedures 10069578 Pneumococcal immunisation PT
    16.1 10042613 - Surgical and medical procedures 10054129 Diphtheria immunisation PT
    16.1 100000004862 10047976 Whooping cough due to bordetella pertussis (B. pertussis) LLT
    16.1 10042613 - Surgical and medical procedures 10069577 Pertussis immunisation PT
    16.1 10042613 - Surgical and medical procedures 10063021 Primary immunisation LLT
    16.1 10042613 - Surgical and medical procedures 10046859 Vaccination LLT
    16.1 10042613 - Surgical and medical procedures 10021430 Immunisation PT
    16.1 10042613 - Surgical and medical procedures 10069533 Haemophilus influenzae type b immunisation PT
    16.1 10018065 - General disorders and administration site conditions 10069620 Vaccination site swelling PT
    16.1 10042613 - Surgical and medical procedures 10039244 Routine vaccination LLT
    16.1 10042613 - Surgical and medical procedures 10034101 Passive immunisation LLT
    16.1 10042613 - Surgical and medical procedures 10039243 Routine immunisation LLT
    16.1 10042613 - Surgical and medical procedures 10039242 Routine childhood immunisation LLT
    Population Age: Under 18, Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2012-004892-37 Sponsor Protocol Number: NL41205.018.12 Start Date*: 2013-03-21
    Sponsor Name:Academic Medical Center
    Full Title: N-Acetylcysteine in patients with Sickle Cell Disease: Reducing the incidence of daily life pain in patients with sickle cell disease
    Medical condition: Sickle Cell
    Disease: Version SOC Term Classification Code Term Level
    15.1 100000004850 10040643 Sickle cell crisis LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Prematurely Ended) BE (Completed) GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2006-006393-14 Sponsor Protocol Number: UDT-1/PHT Start Date*: 2007-10-23
    Sponsor Name:Dr. Falk Pharma GmbH
    Full Title: Double-Blind, Randomised, Parallel-Group, Placebo-Controlled, Multi-Centre Phase II Clinical Study on the Efficacy and Safety of Different Doses of Udenafil in Cirrhotic Patients with Portal Hypert...
    Medical condition: Portal hypertension, liver cirrhosis
    Disease: Version SOC Term Classification Code Term Level
    13.1 10019805 - Hepatobiliary disorders 10036200 Portal hypertension PT
    13.1 10019805 - Hepatobiliary disorders 10024667 Liver cirrhosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) LT (Completed) CZ (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2012-005587-94 Sponsor Protocol Number: 000079 Start Date*: 2013-05-12
    Sponsor Name:Ferring International Pharmascience Center US, Inc.
    Full Title: A Double-blind, Randomised, Placebo-controlled, Phase 3 Trial in Patients with Chronic Idiopathic Constipation to Demonstrate the Efficacy and Safety of Elobixibat 5 mg and 10 mg for 26 Weeks
    Medical condition: Chronic idiopathic constipation
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004856 10072118 Chronic idiopathic constipation LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) DE (Prematurely Ended) CZ (Prematurely Ended) GB (Completed) PL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2011-000811-23 Sponsor Protocol Number: Start Date*: 2012-06-22
    Sponsor Name:University Hospital Southampton NHS Foundation Trust
    Full Title: Treatment of neonatal chronic lung disease (nCLD). The Surfactant, Nutrition and Microorganism Interactions study in infants at risk of developing chronic lung disease - 2 (TSuNaMI-II)
    Medical condition: neonatal chronic lung disease bronchopulmonary dysplasia
    Disease: Version SOC Term Classification Code Term Level
    14.1 10022117 - Injury, poisoning and procedural complications 10063349 Endotracheal intubation complication PT
    14.1 10042613 - Surgical and medical procedures 10044107 Total parenteral nutrition LLT
    14.1 10029205 - Nervous system disorders 10018985 Haemorrhage intracranial PT
    14.1 10021881 - Infections and infestations 10069719 Bacterial colonisation LLT
    14.1 10047065 - Vascular disorders 10021097 Hypotension PT
    14.1 10007541 - Cardiac disorders 10006093 Bradycardia PT
    14.1 10038738 - Respiratory, thoracic and mediastinal disorders 10002974 Apnoea PT
    14.1 10038738 - Respiratory, thoracic and mediastinal disorders 10037395 Pulmonary haemorrhage of fetus or newborn LLT
    14.1 10021881 - Infections and infestations 10040047 Sepsis PT
    14.1 10038738 - Respiratory, thoracic and mediastinal disorders 10035759 Pneumothorax PT
    14.1 10038738 - Respiratory, thoracic and mediastinal disorders 10006475 Bronchopulmonary dysplasia PT
    14.1 10038738 - Respiratory, thoracic and mediastinal disorders 10058490 Hyperoxia PT
    Population Age: Preterm newborn infants, Under 18 Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2010-022338-10 Sponsor Protocol Number: H9H-MC-JBAK Start Date*: 2011-05-03
    Sponsor Name:Eli Lilly and Company
    Full Title: Phase 2 Study of LY2157299 in Patients with Hepatocellular Carcinoma
    Medical condition: Carcinoma, hepatocellular
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10019829 Hepatocellular carcinoma recurrent LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) ES (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2015-004496-71 Sponsor Protocol Number: 104-201508 Start Date*: 2016-03-01
    Sponsor Name:Otonomy Inc.
    Full Title: A prospective, randomized, double blind, placebo-controlled, multicenter, Phase 3 efficacy and safety study of OTO-104 given as a single intratympanic injection in subjects with unilateral Meniere’...
    Medical condition: Meniere's disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 10013993 - Ear and labyrinth disorders 10027183 Meniere's disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) BE (Completed) DE (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2012-000353-31 Sponsor Protocol Number: DEEP-2 Start Date*: 2012-11-29
    Sponsor Name:CONSORZIO PER VALUTAZIONI BIOLOGICHE E FARMACOLOGICHE
    Full Title: Multicentre, randomised, open label, non-inferiority active-controlled trial to evaluate the efficacy and safety of deferiprone compared to deferasirox in paediatric patients aged from 1 month to l...
    Medical condition: Chronic iron overload
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004861 10065974 Chronic iron overload LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: IT (Completed) Outside EU/EEA GR (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2014-001411-39 Sponsor Protocol Number: ABT-002 Start Date*: 2018-09-04
    Sponsor Name:Abeona Therapeutics Inc
    Full Title: Phase I/II gene transfer clinical trial of rAAV9.CMV.hNAGLU for Mucopolysaccharidosis (MPS) IIIB
    Medical condition: MPS IIIB is a devastating lysosomal storage disease, caused by a N-α-acetylglucosaminidase (NAGLU) gene defect. Infants with MPS IIIB appear normal at birth, but the disease is relentlessly progre...
    Disease:
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: ES (Prematurely Ended) DE (Prematurely Ended) FR (Prematurely Ended) GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2018-003748-22 Sponsor Protocol Number: MRG106-11-203 Start Date*: 2019-08-29
    Sponsor Name:miRagen Therapeutics, Inc.
    Full Title: PRISM: An Open-label, Multi-Center Extension Study to Investigate the Efficacy and Safety of Cobomarsen (MRG-106) Following Systemic Treatment in Subjects with Cutaneous T-Cell Lymphoma (CTCL), Myc...
    Medical condition: Cutaneous T-Cell Lymphoma (CTCL), Mycosis Fungoides (MF) Subtype
    Disease: Version SOC Term Classification Code Term Level
    22.0 100000004864 10028483 Mycosis fungoides LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) FR (Prematurely Ended) DE (Prematurely Ended) BE (Completed) ES (Completed) AT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2018-000717-20 Sponsor Protocol Number: CD-TCR-002 Start Date*: 2019-10-09
    Sponsor Name:Medigene AG
    Full Title: Long-Term Follow-Up Clinical Trial of Subjects Treated with PRAME TCR modified T cells, MDG1011
    Medical condition: High Risk Myeloid and Lymphoid Neopolasms
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061240 Malignant lymphoid neoplasm PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10000886 Acute myeloid leukemia LLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10028228 Multiple myeloma LLT
    20.0 100000004851 10028536 Myelodysplastic syndromes HLT
    16.1 100000004851 10028229 Multiple myelomas HLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10028557 Myeloid leukemia, acute LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10028533 Myelodysplastic syndrome PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-003341-15 Sponsor Protocol Number: FFIS/2019/01/AS Start Date*: 2022-10-21
    Sponsor Name:Fundación para la Formación e Investigación Sanitarias de la Región de Murcia (FFIS)
    Full Title: Aspirin versus placebo in twin pregnancies for preeclampsia prevention: A multicentre, randomised, double-blind, placebo-controlled trial.
    Medical condition: Pre-eclampsia
    Disease: Version SOC Term Classification Code Term Level
    20.0 10036585 - Pregnancy, puerperium and perinatal conditions 10036485 Pre-eclampsia PT
    Population Age: Adults Gender: Female
    Trial protocol: ES (Ongoing) AT (Ongoing) DK (Trial now transitioned) IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2007-004235-37 Sponsor Protocol Number: 248.634 Start Date*: 2008-08-19
    Sponsor Name:Boehringer Ingelheim
    Full Title: Long-term safety study of open-label pramipexole extended release (ER) in patients with advanced Parkinson’s disease (PD).
    Medical condition: Male or female patients, with idiopathic PD diagnosed for at least 2 years, 30 years of age or older at time of diagnosis, with a modified Hoehn and Yahr scale of 2 to 4 at on-time.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10061536 Parkinson's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) IT (Completed) CZ (Completed) HU (Completed) AT (Completed) SE (Completed) SK (Completed) PL (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2009-016065-29 Sponsor Protocol Number: GWCA0962 Start Date*: 2010-03-10
    Sponsor Name:GW Pharma Ltd.
    Full Title: A double blind, randomized, placebo-controlled, parallel group study of Sativex oromucosal spray (Sativex®; Nabiximols) as adjunctive therapy in relieving uncontrolled persistent chronic pain in pa...
    Medical condition: Pain in patients with advanced cancer, who experience inadequate analgesia during optimized chronic opioid therapy.
    Disease: Version SOC Term Classification Code Term Level
    15.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10058019 Cancer pain PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) GB (Completed) DE (Completed) PL (Completed) BG (Completed) HU (Completed) RO (Completed)
    Trial results: View results
    EudraCT Number: 2008-000622-40 Sponsor Protocol Number: 12402A Start Date*: 2009-01-21
    Sponsor Name:H. Lundbeck A/S
    Full Title: A randomised, double-blind, parallel-group, placebo-controlled phase III study to evaluate the efficacy and safety of desmoteplase in subjects with acute ischemic stroke.
    Medical condition: Acute ischemic stroke within 3 - 9 hours after the onset of symptoms.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10055221 Ischemic stroke LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Prematurely Ended) HU (Completed) AT (Completed) DE (Prematurely Ended) FR (Completed) ES (Completed) EE (Completed)
    Trial results: View results
    EudraCT Number: 2009-014339-19 Sponsor Protocol Number: ONO-4641POU006 Start Date*: 2010-03-26
    Sponsor Name:ONO Pharmaceutical Co., Ltd.
    Full Title: A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF THE SAFETY AND EFFICACY OF ONO-4641 IN PATIENTS WITH RELAPSING-REMITTING MULTIPLE SCLEROSIS
    Medical condition: Relapsing-remitting Multiple Sclerosis
    Disease: Version SOC Term Classification Code Term Level
    12.1 10063399 Relapsing-remitting multiple sclerosis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: CZ (Completed) BE (Completed) ES (Completed) DE (Completed) GR (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 4  5  6  7  8  9  10  11  12  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun Jul 13 06:24:56 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA